Company news
Algorae Pharmaceuticals Limited (ASX:1AI) news
Algorae Pharmaceuticals Limited news releases on 6ix. Latest, Mar 1, 2023: LCT Undertakes $2.5 Million Capital Raise Initiative
Press releases — page 2
LCT Undertakes $2.5 Million Capital Raise Initiative
February 28, 2023
Half Year Accounts and Appendix 4D
February 27, 2023
Trading Halt
February 26, 2023
Quarterly Activity Report and Appendix 4C
October 28, 2022
New milestone for LCTs AI development
September 16, 2022
Preliminary Final Report and 2022 Financial Statements
August 31, 2022
LCT Completes Strategic A$1.285M Placement
May 30, 2022
Half Yearly Report and Accounts
February 25, 2022
LCT Signs Service Agreement with NZeno
January 23, 2022
Results of Rights Issue
December 28, 2021
Extension of Rights Issue
December 8, 2021
Prospectus- Rights Issue
November 14, 2021
LCT- Rights Issue
November 14, 2021
LCT Receives New Zealand R&D Tax Credit
November 9, 2021
LCT Advises Price Change for Rights Issue
November 7, 2021
LCT Signs MOU with NZeno, Secures Pig Cells for NTCELL Trial
October 26, 2021
Secures Funds for 3rd Trial of NTCELL in Parkinson Disease
October 18, 2021
Preliminary Final Report and 2021 Financial Statements
August 31, 2021
LCT Interim CEO Appointed
July 15, 2021
LCT exits peptide projects
March 28, 2021
LCT CEO Dr Ken Taylor signals intention to retire
January 25, 2021
Preliminary Final Report and 2020 Financial Statements
August 31, 2020
Amended Appendix 4C
July 30, 2020
Response to ASX Aware Query
July 12, 2020
Appendix 4C - quarterly
April 29, 2020
LCT extends cash runway with receipt from Vertex acquisition
October 15, 2019
LCT to benefit from Semma Therapeutics acquisition by Vertex
September 18, 2019
Preliminary Final Report and 2019 Financial Statements
August 29, 2019
NTCELL Parkinsons trial patient data 2 years after implant
May 12, 2019
NTCELL Parkinsons trial patient data at 18 months
November 1, 2018
Preliminary Final Report and 2018 Financial Statements
August 30, 2018
NTCELL and Parkinsons trial update
May 14, 2018
LCT Strategy Update
April 11, 2018
LCT to sell JV Shares and receive DIABECELL licence
January 25, 2018
Appendix 4C - Quarterly
January 23, 2018
Results of LCT Parkinsons trial require further analysis
November 9, 2017
LCT files pericyte protective agent provisional patent
November 7, 2017
Appendix 4C Quarterly Cash Flow Report 30 September 2017
October 18, 2017
Preliminary Final Report and Financial Statements
August 23, 2017
NTCELL continues to halt progression of Parkinsons disease
June 6, 2017
LCT collaborates with CBR to extend product pipeline
May 16, 2017
Treatment completed for all patients in Parkinsons trial
April 30, 2017
Living Insights Newsletter February 2017
February 27, 2017
Approval granted for group 3 in Parkinsons trial
February 7, 2017
US choroid plexus cells patent application published
January 11, 2017
Group 2 Parkinsons trial patients treatment completed
December 22, 2016
Reinstatement to Official Quotation
November 29, 2016
Suspension from Official Quotation
November 27, 2016
Approval granted for group 2 in Parkinsons trial
November 10, 2016
Appendix 4C Quarterly Cash Flow Report 30 September 2016
October 19, 2016